Gajewski TF - Search Results

1

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.

Kline J, Gajewski TF. Kline J, et al. Among authors: gajewski tf. Curr Opin Investig Drugs. 2010 Dec;11(12):1354-9. Curr Opin Investig Drugs. 2010. PMID: 21154117 Review.

2

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. Blank C, et al. Among authors: gajewski tf. Cancer Res. 2004 Feb 1;64(3):1140-5. doi: 10.1158/0008-5472.can-03-3259. Cancer Res. 2004. PMID: 14871849

3

Negative regulation of T-cell function by PD-1.

Zha Yy, Blank C, Gajewski TF. Zha Yy, et al. Among authors: gajewski tf. Crit Rev Immunol. 2004;24(4):229-37. doi: 10.1615/critrevimmunol.v24.i4.10. Crit Rev Immunol. 2004. PMID: 15588223 Review.

4

Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.

Gajewski TF. Gajewski TF. Curr Opin Investig Drugs. 2004 Dec;5(12):1279-83. Curr Opin Investig Drugs. 2004. PMID: 15648949 Review.

5

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.

Gajewski TF. Gajewski TF. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s. doi: 10.1158/1078-0432.CCR-05-2517. Clin Cancer Res. 2006. PMID: 16609053 Review.

6

Immune resistance orchestrated by the tumor microenvironment.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Gajewski TF, et al. Immunol Rev. 2006 Oct;213:131-45. doi: 10.1111/j.1600-065X.2006.00442.x. Immunol Rev. 2006. PMID: 16972901 Review.

7

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.

Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Brown IE, et al. Among authors: gajewski tf. J Immunol. 2006 Oct 1;177(7):4521-9. doi: 10.4049/jimmunol.177.7.4521. J Immunol. 2006. PMID: 16982889

8

The expanding universe of regulatory T cell subsets in cancer.

Gajewski TF. Gajewski TF. Immunity. 2007 Aug;27(2):185-7. doi: 10.1016/j.immuni.2007.08.001. Immunity. 2007. PMID: 17723212 Free article.

9

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Gajewski TF. Gajewski TF. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61. doi: 10.1158/1078-0432.CCR-07-0892. Clin Cancer Res. 2007. PMID: 17875753 Review.

10

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Kline J, et al. Among authors: gajewski tf. Clin Cancer Res. 2008 May 15;14(10):3156-67. doi: 10.1158/1078-0432.CCR-07-4696. Clin Cancer Res. 2008. PMID: 18483384

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters